JP2020533270A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533270A5
JP2020533270A5 JP2019560097A JP2019560097A JP2020533270A5 JP 2020533270 A5 JP2020533270 A5 JP 2020533270A5 JP 2019560097 A JP2019560097 A JP 2019560097A JP 2019560097 A JP2019560097 A JP 2019560097A JP 2020533270 A5 JP2020533270 A5 JP 2020533270A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
receptor agonist
serotonin receptor
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019560097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/030448 external-priority patent/WO2018204359A1/en
Publication of JP2020533270A publication Critical patent/JP2020533270A/ja
Publication of JP2020533270A5 publication Critical patent/JP2020533270A5/ja
Pending legal-status Critical Current

Links

JP2019560097A 2017-05-01 2018-05-01 眼の病態を治療するための組成物および方法 Pending JP2020533270A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762492841P 2017-05-01 2017-05-01
US62/492,841 2017-05-01
PCT/US2018/030448 WO2018204359A1 (en) 2017-05-01 2018-05-01 Compositions and methods for treating ocular pathologies

Publications (2)

Publication Number Publication Date
JP2020533270A JP2020533270A (ja) 2020-11-19
JP2020533270A5 true JP2020533270A5 (https=) 2021-05-27

Family

ID=64017034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019560097A Pending JP2020533270A (ja) 2017-05-01 2018-05-01 眼の病態を治療するための組成物および方法

Country Status (8)

Country Link
US (1) US11759438B2 (https=)
EP (1) EP3618850A4 (https=)
JP (1) JP2020533270A (https=)
KR (2) KR20230135163A (https=)
CN (1) CN110662549A (https=)
AU (2) AU2018263853A1 (https=)
CA (1) CA3061900A1 (https=)
WO (1) WO2018204359A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4219498A1 (en) * 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
JPWO2023048174A1 (https=) * 2021-09-22 2023-03-30
WO2024010765A1 (en) * 2022-07-05 2024-01-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions for treating 5-ht2 conditions and methods of using the same
AU2023317872A1 (en) 2022-08-04 2025-03-13 Synex Holdings Bv Prodrugs of substituted ergolines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554617A (en) * 1979-09-28 1996-09-10 The Upjohn Company Method for treating cancer with 6-aryl pyrimidine compounds
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
WO1996014060A1 (en) * 1994-11-04 1996-05-17 Marklund Stefan L Use of receptor agonists to stimulate superoxide dismutase activity
US20090191288A1 (en) * 1996-02-12 2009-07-30 Squires Meryl J Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
DE69710258T2 (de) * 1996-06-17 2002-08-22 Mitsubishi Chemical Corp., Tokio/Tokyo Mittel zur Beschleunigung des Tränenflusses enthaltend einen Serotonin-Liganden, insbesondere Aminoalkoxybibenzyle
JPH1067684A (ja) * 1996-06-17 1998-03-10 Mitsubishi Chem Corp 涙液分泌促進剤
US20030207890A1 (en) * 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2006029182A2 (en) * 2004-09-07 2006-03-16 The La Jolla Institute For Molecular Medicine Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
US8859579B2 (en) * 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
US9642819B2 (en) * 2008-07-10 2017-05-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
US9271980B2 (en) * 2009-08-03 2016-03-01 Daljit Singh Dhanoa Deuterium-enriched pyrimidine compounds and derivatives
TWI719277B (zh) * 2011-11-14 2021-02-21 美商安斯泰來再生醫藥協會 人類rpe細胞之醫藥組合物及其用途
US8877183B2 (en) * 2012-06-26 2014-11-04 National Institutes Of Health (Nih) Methods for treatment of ocular diseases
US11033554B2 (en) 2015-07-24 2021-06-15 United States Government As Represented By The Department Of Veterans Affairs Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration

Similar Documents

Publication Publication Date Title
JP2020533270A5 (https=)
JP6494528B2 (ja) フッ化インテグリンアンタゴニスト
JP2021515777A (ja) 眼科用製剤
US12370209B2 (en) Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
CN107708738B (zh) 含有柠檬酸酯的贮库制剂
JP2014533275A5 (https=)
CN101678006A (zh) 含有非麦角类的选择性d2受体激动剂作为有效成分的后眼部疾病的预防或治疗剂
JP2011530496A (ja) 眼新生血管形成症状の治療のためのソラフェニブを含む眼科用医薬組成物
JP2025106418A (ja) エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
JP2021503449A5 (https=)
JP2013500977A5 (https=)
CN115103842A (zh) 用于治疗眼部疾病的组合物
ME02608B (me) Kombinacija, komplet i postupak snižavanja intraokularnog pritiska
CN110662549A (zh) 用于治疗眼病的组合物和方法
US10537563B2 (en) Methods for treating ocular disease using inhibitors of CSF-1R
JP2019534269A5 (https=)
JP2021138710A5 (https=)
JP2005047909A (ja) ピペリジン誘導体を有効成分とする掻痒治療剤
JP2020530459A5 (https=)
CA3014071C (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
JP2009517375A (ja) 眼の疾患の治療
JP2020114847A5 (https=)
HK40073052A (en) Medical use of 5'-adenosine diphosphate ribose (adpr)
AU2023221950A1 (en) Treatment of anatomical and functional retinal atrophies
TW201639589A (zh) 含有多肽之醫藥組成物